Pfizer cuts CRO unicorn from Lyme vaccine trial in dispute over conduct
Pfizer is ending its work with research contractor Care Access on an 18,000-patient Lyme disease vaccine trial, according to an internal email reviewed by Endpoints News, widening the breach that has emerged between the drug giant and the richly-valued research startup in recent days.
Last week, Pfizer said it was removing thousands of patients recruited by Care Access from the Phase III work, citing issues with how Care Access had conducted its part of the trial. At the time, it was unclear whether any collaboration between the companies on the Lyme research would continue and if Care Access would recruit new patients.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.